GeneThera to Institute Strategic Plan

The Mezey Howarth Group has been retained to assist GeneThera, Inc. (OTCBB: GTHA) in increasing the shareholder value of the company. Mezey Howarth is working with GeneThera to create and institute a corporate plan that will increase the shareholder value of the company.

The initial focus of Mezey Howarth is to investigate companies that have increasing revenues and positive cash flow in the heath care field and/or biotech field as possible acquisition targets for GeneThera. The acquisition will be the first step of the overall plan where shareholder value is increased through growing revenues, increasing margins, maximizing return on assets and effective governance.

"To maximize shareholder wealth, management must generate, evaluate, and select business strategies that will increase the value of the company," said J. Wade Mezey of The Mezey Howarth Group. "The ability to grow a company through an acquisition is extremely beneficial when there is a synergy business fit and a detailed integration plan is in place."

"The value of any company is a function of the future cash flows it is expected to generate," said Mezey. "As such we have begun developing and implementing a strategic plan with GeneThera with that in mind. The targets we have been in contact with all have doubled their revenues in each of the past three years and are profitable."

"We are excited by the preliminary discussions we have had with potential acquisition targets for GeneThera but an acquisition is only the first step," said Paul Howarth of The Mezey Howarth Group. "The company must institute a strategic plan that includes maximizing the companies return on its assets and effective governance."

"We are excited about the bright future of GeneThera as it propels its strategic growth plan," said Mezey.

"Safe Harbor" Statement: Certain statements in this release are "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. Such statements are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the Company's ability to meet the terms and conditions required to obtain its project financing, risks and delays associated with product development, risk of market acceptance of new products, risk of technology or product obsolescence, competitive risks, reliance on development partners and the need for additional capital.